Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Oncology
Vol. 2, Issue 2, 2015 April 27, 2015 EDT

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia

Melea A. Ward , Gang Fang , Kristy L. Richards , Christine M. Walko , Stephanie R. Earnshaw , Laura E. Happe , Susan J. Blalock ,
  • oncology
  • hematology
  • treatment interruption
  • tyrosine kinase inhibitors
  • chronic myeloid leukemia
ccby-4.0 • https://doi.org/10.36469/9899
JHEOR
1.
Ward MA, Fang G, Richards KL, et al. Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia. JHEOR. 2015;2(2):181-191. doi:10.36469/9899
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)
Powered by Scholastica, the modern academic journal management system